EasyNAT Monkeypox Virus Assay
Ongoing Challanges
The monkeypox epidemic is expanding in East and Central Africa. The number of cases reported in 2024 (as of August 14) has already exceeded the 2023 total, with over 15,600 cases and 537 deaths.[1] Due to potential for further spread, the WHO declared the outbreak a PHEIC on August 14, 2024.
The WHO recommends Nucleic Acid Amplification Testing (NAAT) for viral DNA as the preferred diagnostic method.
Product Overview
The EasyNAT® Monkeypox Virus Assay is a POCT DNA test intended for the rapid qualitative detection of monkeypox virus DNA in oropharyngeal swab and skin lesion (rash) exudate swab samples.
Results available within 49 minutes
Accurate LOD: Oropharyngeal swab: 200 copies/mL; Skin lesion exudate: 500 copies/mL
Compatible with multiple sample types from the oropharynx and skin lesions.
Clinical Value
Ensures accurate results, simplifies testing, and offers flexible, timely reporting.
POC PCR systems offer critical advantages over traditional lab-based testing in outbreak settings.
Distinguishes MPXV from other poxviruses, enabling rapid isolation and contact tracing.
